News from depomed, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Apr 13, 2015, 08:00 ET

Depomed Announces Gralise® ANDA Litigation Settlement Confirming Exclusivity to 2024 and Dismissing Appeal

Depomed, Inc. (Nasdaq: DEPO) today announced it has entered into a settlement agreement with Actavis, Inc. in Depomed's patent infringement...

Apr 02, 2015, 16:05 ET
Mar 17, 2015, 08:32 ET

Depomed Announces Termination of Hart-Scott-Rodino Waiting Period for Pending Acquisition of NUCYNTA® Franchise from Janssen Pharmaceuticals

 Depomed, Inc. (Nasdaq: DEPO), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act)...

Mar 12, 2015, 16:05 ET

Depomed Secures $575 Million Debt Facility From Deerfield and Pharmakon to Finance the Closing of NUCYNTA® Acquisition

Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement with Deerfield and Pharmakon Advisors, LP to...

Mar 03, 2015, 08:00 ET

Depomed To Present At 27th Annual Roth Conference

Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the 27th Annual Roth Conference in Laguna Niguel, California.  The...

Feb 23, 2015, 16:01 ET

Depomed Reports Fourth Quarter and Full Year 2014 Financial Results

 Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter and twelve months ended...

Feb 12, 2015, 08:00 ET

Depomed To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015

Depomed, Inc. (NASDAQ:DEPO) today announced that it will release fourth quarter fiscal year 2014 financial results after the market closes...

Feb 09, 2015, 08:00 ET
Depomed Logo

New American Headache Society Assessment of Acute Migraine Treatments Highlights Effective Therapies Based on Strength of Evidence

A new evidence-based assessment of acute migraine treatments published in the current issue of the American Headache Society (AHS)...

Feb 04, 2015, 08:00 ET

Depomed To Present At Healthcare Conferences In February

 Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at two healthcare conferences in February. The 2015 Leerink Global...

Jan 15, 2015, 16:04 ET

Depomed to Acquire U.S. Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended release tablets and NUCYNTA® (tapentadol) Oral Solution from Janssen Pharmaceuticals, Inc. for $1.05 billion

Depomed, Inc. (NASDAQ: DEPO) today announced that it has entered into a definitive agreement to acquire the U.S. rights to the NUCYNTA...

Nov 20, 2014, 16:05 ET

Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference

Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Piper Jaffray 26th Annual Healthcare Conference in New York...

Nov 12, 2014, 08:00 ET

Depomed To Present At Stifel 2014 Healthcare Conference

 Depomed, Inc. (NASDAQ:DEPO) today announced that it will be presenting at the Stifel 2014 Healthcare Conference in New York City. The...

Nov 05, 2014, 16:05 ET

Depomed Reports Third Quarter 2014 Financial Results

Depomed, Inc. (Nasdaq: DEPO) today reported financial results and highlighted operational achievements for the quarter ended September 30,...

Oct 27, 2014, 16:01 ET

Depomed To Report Third Quarter Fiscal Year 2014 Financial Results On Wednesday, November 5, 2014

 Depomed, Inc. (NASDAQ: DEPO) today announced that it will release third quarter fiscal year 2014 financial results after the market closes...

Sep 05, 2014, 14:34 ET

Depomed Summary Judgment Motion Granted in Suit against FDA Seeking Orphan Drug Exclusivity for Gralise® (Gabapentin)

Depomed, Inc. (Nasdaq:DEPO) today announced that Judge Kentaji Brown Jackson of the federal district court for the District of Columbia has granted...

Sep 04, 2014, 07:00 ET

Depomed Announces Pricing of Upsized $300 Million Convertible Senior Notes Due 2021

 Depomed, Inc.  (Nasdaq: DEPO) today announced that it has priced its registered offering of $300 million aggregate principal amount of...

Sep 02, 2014, 16:00 ET

Depomed Announces Offering of $230 Million Convertible Senior Notes Due 2021

Depomed, Inc. (Nasdaq: DEPO) today announced that it intends to offer, subject to market and other conditions, $230 million aggregate principal...

Aug 25, 2014, 16:01 ET

Depomed To Present At Morgan Stanley 2014 Global Healthcare Conference

Depomed, Inc. (NASDAQ: DEPO) today announced that it will be presenting at the Morgan Stanley 2014 Global Healthcare Conference in New York...

Aug 19, 2014, 11:15 ET

Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024

 Depomed, Inc. (Nasdaq: DEPO) today announced Judge Joel A. Pisano of the U.S. District Court for the District of New Jersey has ruled in favor...

Aug 06, 2014, 16:05 ET

Depomed Reports Second Quarter 2014 Financial Results

 Depomed, Inc. (Nasdaq: DEPO) today reported financial results for the quarter ended June 30, 2014. Second...